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Abstract
Background: Human papillomavirus (HPV) infection is a pre-requisite for cervical cancer, which represents the third
most common cancer among women worldwide. A causal relationship also exists between HPV and cancer in
other areas of the female reproductive system including the vagina and vulva. Whilst the incidence of vaginal
cancer in the UK has remained relatively stable over the past 25 years, vulval cancer rates are increasing. A body of
literature exists on the epidemiology and aetiology of vaginal and vulval cancer, but little is known about the
economic burden. The objective of this study was to quantify the costs of treating these cancers on the National
Health Service (NHS) in England.
Methods: Inpatient and outpatient episodes were derived from Hospital Episode Statistics (HES). Health Resource
Group (HRG) tariffs and National Reference Costs were used to estimate the cost of treating pre-cancerous and
invasive vaginal and vulval lesions in England.
Results: The study showed that for the 5 years from 2009/2010 to 2014/2015 the total cost associated with pre-
cancerous and invasive vaginal and vulval lesions was over £14 million per year on average (95% of which was
attributed to inpatient costs). Vulval cancer accounted for the largest proportion; an estimated 60% of the total cost
(£8.82 million). On average 4316 patients per year in England were admitted to hospital and 912 patients attended
outpatient settings for pre-cancerous and invasive disease of the vagina and vulva.
Conclusion: The results indicate that vaginal and vulval cancer cost the English health care system over £14 million
per year. Given the causal role of HPV in a proportion of these cancers, preventative measures such as the national
HPV immunisation programme have the potential to reduce the economic burden. To ensure optimal use of NHS
resources, it is important that future economic evaluations of such preventative measures consider the full burden
of HPV related disease.
Keywords: Human papillomavirus, Vaginal cancer, Vulval cancer, Retrospective, Resource use, Cost, England,
Hospital Episode Statistics
Background
Human papillomavirus (HPV) is one of the most preva-
lent sexually transmitted diseases worldwide with over
100 strains currently recognised, many of which are
spread through sexual contact [1].
It is estimated that 75 to 80% of sexually active indi-
viduals will become infected with HPV in their lifetime
[2, 3]. Reports suggest that sexually active women under
25 years are most at risk of HPV infection. The risk of
HPV infection increases with multiple sexual partners
and with lower age at first intercourse. Most infections
are harmless and cleared by the immune system, usually
within 24months, but persistent infection can be car-
cinogenic. HPV is a fundamental cause of cervical cancer
and is aetiologically associated with cancers at other
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sites, including the vagina and vulva. Current data sug-
gest that HPV infection may be associated with approxi-
mately 25% of vulval cancers and approximately 78% of
vaginal cancers globally [4]. As with other ano-genital
cancers, the susceptibility to vaginal and vulval cancer
also increases with age [5–7]. While the age-
standardised incidence of vaginal cancer has remained
relatively stable over the past 25 years, vulval cancer is
on the rise, with a 12% increase in age-standardised inci-
dence rates seen between 2004 and 2006 and 2014–2016
[5, 6].
Treatment of vaginal and vulval cancers involves surgi-
cal intervention - ranging from ablation and local exci-
sions to vaginectomy and vulvectomy - as well as
radiotherapy and chemotherapy. The costs of treating
vaginal and vulval cancers in England are poorly under-
stood. Published economic evaluations of HPV immun-
isation use estimations based on the cost of cervical
cancer or non-cervical cancers in other countries [8–11].
Thus, at present there is an unmet need in terms of pub-
lished estimates of the costs associated specifically with
vaginal and vulval cancers in England.
The objective of this study is to provide an update of
the current inpatient and outpatient activity related to
these cancers and concurrently estimate the healthcare
costs associated with treatment.
Methods
To estimate the costs of treating vaginal and vulval can-
cers from an English healthcare perspective, a retro-
spective (non-comparative) case series analysis was
conducted using patient level data extracted from the
Hospital Episode Statistics (HES) database. HES includes
records of all care funded by the English NHS (all ad-
missions, accident & emergency attendances and out-
patient appointments at NHS hospitals in England),
allowing estimation of the secondary care treatment
costs associated with pre-cancerous and invasive vaginal
and vulval cancer lesions in England. More information
on the patient population included in the HES database
are available from the NHS digital website [12]. Based
on advice from a clinician specializing in gynaecological
oncology, admitted patient care (APC) (inpatient) re-
cords were identified based on the presence of primary,
secondary or tertiary diagnosis of the following ICD-10
codes: C52 – vaginal cancer, C51 – vulval cancer, D072
and N89 – vaginal dysplasia, D071 and N90 – vulval
dysplasia. Data on outpatient attendances were extracted
for the same list of ICD-10 codes but were confined to
records with a primary or secondary diagnosis only,
reflecting the more disease specific nature of post-
treatment care.
In accordance with the National Tariff/Payment by Re-
sults (PbR) policy, the annual management costs for pre-
invasive and invasive vaginal and vulval lesions were esti-
mated from the health payers’ perspective [13].
HES data collection
All finished consultant episodes (FCE) and outpatient at-
tendances related to one of the selected ICD-10 codes
were extracted from the HES database along with anon-
ymised patient identification numbers to estimate the
annual number of hospitalised patients. Records were
extracted between the data years of 2009/10 and 2014/
15. The time frame for analysis was restricted to these
data years because these were the latest full-year data
available from HES at the time of data request. No other
inclusion or exclusion criteria were applied.
Data aggregation and costing
The number of patients undergoing treatment for vagi-
nal or vulval cancer in each year of the study period was
determined by tracing the unique patient identifiers
(HESID) assigned to each FCE. Mean annual patient
numbers were then calculated. NHS funded healthcare
providers in England are reimbursed under the Payment
by Results (PbR) scheme [14]. The currencies for pay-
ment under PbR are healthcare resource groups (HRG).
Each year, payment tariffs for each HRG are determined
using retrospective analysis of costing data submitted
from previous years. In order to derive relevant HRGs
for care delivered to vaginal and vulval cancer patients,
inpatient FCEs were aggregated into spells of care (from
hospital admission to discharge) using software publicly
available from the NHS [15]. Although most spells com-
prise a single FCE under the care of one consultant from
admission to discharge, in some cases spells are spread
across several FCEs. A spell is also a more robust activity
measure than an FCE as the latter can be easily influ-
enced (e.g., by transferring patients between consul-
tants). The 2016/17 local payment grouper was used to
group FCEs into spells of care and derive a single
Healthcare Resource Group (HRG) [15]. Core HRGs
were then cross-referenced with the National Tariff
2016/17 (reflecting 2016 costs) to estimate the associated
spell cost. Costing analyses were performed in Microsoft
Excel 2016. Standard deviations were computed
in Microsoft Excel using the 2009–2014 total cost num-
bers and were calculated using standard methods, i.e., by
taking the square root of the variance, the variance being
the average of the squared difference of each total cost
per year subtracted from the mean total cost over the
2009/2010–2014/2015 time frame.
The hospital cost per patient was calculated by first
calculating the total HRG costs for each spell recorded
in the data across all patients per year. Following this
the average hospital cost per patient was calculated by
dividing the total HRG costs in a given year by the
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annual number of hospitalised patients in that specific
year. For inpatients, the costs associated with the spell of
care included all costs associated with the initial diagno-
sis (if this took place in a hospital), surgical procedures
and hospital-based medical treatments. Outpatient costs
were estimated by grouping consultations by treatment
specialty based on Treatment Function Codes (TFCs)
and whether the consultation was the first of a series or
a follow-up. As with the inpatient data, all activities for
which reimbursement rates are locally negotiated, such
as outpatient chemotherapy and radiotherapy sessions,
were disaggregated from the core HRG. For specific
types of therapy, including but not limited to chemo-
therapy, radiotherapy and rehabilitation, costs are not in-
cluded within the National Tariff due to wide regional
variations in fees and practice. For such therapies, the
HRGs derived from the HES data were cross-referenced
with the 2016 National Reference Costs [16].
Each data extract was validated and cleaned prior to
delivery by NHS Digital [12, 17]. A second cleaning
process was conducted, checking for duplicates and
missing fields that may impede the grouping process.
Any data that could not be matched with the grouper
was excluded from the costing analysis. Data was proc-
essed using Microsoft Excel 2016.
Some FCEs could not be grouped due to inaccurate
coding or missing codes within data fields. Because of
missing codes, three types of error were mostly seen.
These were FCE error counts, spell error counts and the
exclusion of errors and missing data in the age field. In
these cases (ranging between 0.36% of records for vagi-
nal dysplasia and 1.61% of records for vaginal cancer), a
‘UZ01Z’ HRG code was generated, which is defined as
‘Data invalid for grouping’. Table 1 shows the number of
errors seen, and therefore the number of records ex-
cluded from the analysis at the grouper stage, stratified
by ICD-10 code per year. We did not impute any values.
The grouper carried out the exclusions in a systematic
manner.
Missing data is a result of poor clinical coding in the
initial phase of data collection and cannot be rectified.
This is a limitation of the current analyses which could
lead to potential underestimations of the true costs,
however, where possible all records (regardless of miss-
ing data) were included in the patient demographic
analysis.
Results
Study sample overview
Between 2009/10 and 2014/15, an average of 4316 pa-
tients were admitted to hospital each year in England for
vaginal or vulval related cancer or dysplasia. The most
frequent diagnoses were related to diseases of the vulva
(vulval dysplasia mean inpatients = 1726, and vulval
cancer mean inpatients = 1621). On average, age at diag-
nosis was higher for invasive cancer cases than for dys-
plasia cases. Furthermore, across all lesion types,
patients presenting with diseases of the vulva were older
on average than those with vaginal disease, with a mean
age at diagnosis ranging from 49 for vaginal dysplasia to
68 for vulval cancer (Table 2). The data shows a trend
towards an increasing number of inpatients admitted for
Table 1 Missing values as identified from the HRG Grouper per
ICD-10 code per year
ICD-10 Description Year FCE Error Count Spell Error Count
C51 Vulval Cancer 2009/10 83 59
2010/11 76 52
2011/12 104 84
2012/13 32 14
2013/14 20 7
2014/15 22 8
N90 Vulval Dysplasia 2009/10 30 3
2010/11 39 4
2011/12 43 7
2012/13 49 2
2013/14 53 5
2014/15 51 4
D071 Vulval Dysplasia 2009/10 34 8
2010/11 57 8
2011/12 53 8
2012/13 52 1
2013/14 56 2
2014/15 59 6
C52X Vaginal Cancer 2009/10 20 14
2010/11 15 12
2011/12 95 60
2012/13 2 2
2013/14 31 28
2014/15 22 21
N89 Vaginal Dysplasia 2009/10 18 1
2010/11 14 1
2011/12 20 1
2012/13 32 1
2013/14 29 1
2014/15 23 1
D072 Vaginal Dysplasia 2009/10 12 2
2010/11 13 2
2011/12 20 7
2012/13 10 1
2013/14 17 1
2014/15 10 2
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vulval dysplasia over time, with a 11% increase from
2009/10 to 2014/15 (Table 2). This mirrors published re-
ports on the increasing incidence of vulval cancers in
the UK [5, 6].
Outpatient attendances
For the diseases of interest over the period studied 912
patients on average attended outpatient facilities each
year. The most frequent diagnoses were vulval cancer
(mean patients = 349), and vaginal dysplasia (mean pa-
tients = 261) (Table 3). The number of patients receiving
outpatient treatment for vaginal dysplasia suddenly and
disproportionately increased from 2012/13 (93) to 2013/
14 (681).
Hospital spells
On average, 7077 hospital spells (across 4316 patients
who experienced at least one hospital spell) and 3834
outpatient attendances (across 912 patients who re-
corded an outpatient visit) each year were recorded
across all conditions studied. Annually, the average vagi-
nal cancer inpatient had 3 hospital spells and the average
vaginal cancer outpatient had 9 outpatient attendances.
This was lower on average for vulval cancer patients (2
hospital spells / 7 outpatient attendances per year). Dys-
plasia patients had fewer hospital visits (1 hospital spell
and 1 outpatient attendance per year on average). Mean
spell durations were highest for invasive vulval cancer (5
days) and invasive vaginal cancer (3 days). Ranging from
82% for invasive cancers to 97–98% for dysplasia, most
hospital spells were elective admissions. Elective day case
admissions were observed in 42% of vaginal cancer, 26%
of vulval cancer, 73% of vaginal dysplasia, and 67% of
vulval dysplasia hospital spells. Excess bed days were ob-
served in 10% of vulval cancer hospital spells and in ≤3%
of spells for all other conditions studied.
Treatment costs
The mean annual cost per patient (setting dependent) is
provided in Table 3. Mean annual inpatient costs were
highest for the invasive cancers, at £5335 for vaginal
cancer and £5173 for vulval cancer. Dysplasia were asso-
ciated with lower inpatient costs of between £1250 and
£1487 on average per year. The same pattern was seen
for outpatients, where costs associated with invasive can-
cer patients were £1850 for vaginal cancer and £1231 for
vulval cancer, and those associated with dysplasia ranged
from £228 to £401 on average per year. Across all dis-
eases and sites, 95% of costs were attributable to inpa-
tients (£13.95 million vs £777,000). Table 4 provides a
breakdown of the mean annual inpatient and outpatient
cost per type of cost category. In PbR, bundled costs
Table 2 Incidence of Vaginal and Vulval Cancer Over Time
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Vaginal Cancer
Inpatient Numbers (HES data) – – – – – 428 436 460 425 453 427 – –
Outpatient Numbers (HES data) – – – – – 82 78 127 71 126 158 – –
Age-Standardised Incidence Rate per 100,000 (Cancer Research
Statistics)
0.8 0.9 0.9 0.8 0.8 0.9 0.9 0.9 0.8 0.8 0.8 0.7 0.8
Vulval Cancer
Inpatient Numbers (HES data) – – – – – 1577 1560 1591 1736 1644 1619 – –
Outpatient Numbers (HES data) – – – – – 199 193 282 376 434 612
Age-Standardised Incidence Rate per 100,000 (Cancer Research
Statistics)
3.5 3.5 3.7 3.8 3.9 4.0 3.9 3.9 4.1 4.2 4.0 4.1 3.9
Table 3 Inpatient and outpatient admission statistics
Mean Age at
Diagnosis in Years
Mean Annual
Inpatients
Annual Inpatient Cost
per Patient (SD)
Mean Annual
Outpatients
Annual Outpatient Cost
per Patient (SD)
Total Annual Cost of
Disease (SD)
Vaginal
Cancer
61.2 438 £5335 (£176) 107 £1850 (£536) £2,535,631 (£84,
825)
Vulval
Cancer
68.5 1621 £5173 (£386) 349 £1231 (£166) £8,816,813 (£553,
570)
Vaginal
Dysplasia
49.5 531 £1250 (£96) 261 £401 (£102) £767,634 (£113,141)
Vulval
Dysplasia
54.3 1726 £1487 (£31) 195 £228 (£29) £2,609,937 (£113,
442)
Total 4316 912 £14,730,015 (£478,
362)
(SD Standard deviation); Total numbers are provided in Bold
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include all care received in a hospital setting except
unbundled HRGs such as chemotherapy, radiotherapy,
rehabilitation, palliative care, specific diagnostic imaging
and high cost drugs. Unbundled HRGs were introduced
by PbR to make it possible to separately report, cost and
remunerate these different components within a care
pathway away from the traditional hospital setting.
Chemotherapy and radiotherapy have been disaggre-
gated from other unbundled costs for the purposes of
this research. Across all conditions studied, 9% of costs
were attributable to unbundled costs, but this varied by
disease and site (Table 4, Fig. 1). On average, the
proportion of total costs attributed to unbundled ele-
ments of care, including chemotherapy and radiotherapy,
is highest in invasive cancers (24.8% in vaginal cancer
and 18.2% in vulval cancer). Radiotherapy is a key treat-
ment option in vulval cancer patients, with 39.2% of all
outpatient treatment costs being attributed to such ther-
apy. In vaginal cancer patients, almost half of all out-
patient treatment costs are due to rehabilitation
(including physical rehabilitation, psychological support,
and provision of information) and palliative care, dem-
onstrating the sometimes lengthy and intense post-
surgery care these patients can experience. As would be
Table 4 Mean annual cost per genital cancer and dysplasia per type of care
Inpatient
Disease of Interest Bundled (SD) Unbundled* (SD) Chemotherapy (SD) Radiotherapy (SD) Total (SD)
Vaginal Cancer £1,824,341 (£124,012) £26,654 (£3028) £382,057 (£55,121) £104,575 (£5412) £2,337,628 (£104,567)
Vulval Cancer £7,871,209 (£618,739) £57,153 (£10,785) £352,365 (£59,023) £106,098 (£17,420) £8,386,826 (£612,849)
Vaginal Dysplasia £652,098 (£51,321) £1436 (£1114) £6156 (£6927) £3107 (£3810) £662,798 (£54,641)
Vulval Dysplasia £2,557,355 (£134,342) £4194 (£2453) £3262 (£2603) £705 (£1226) £2,565,516 (£131,438)
Total £12,905,004 (£591,585) £89,438 (£11,367) £743,840 (£105,324) £214,486 (£17,401) £13,952,767 (£573,092)
Outpatient
Vaginal Cancer £81,897 (£37,748) £91,068 (£23,366) £10,703 (£8501) £14,334 (£9140) £198,003 (£69,410)
Vulval Cancer £222,895 (£132,128) £18,424 (£9171) £20,109 (£17,461) £168,558 (£63,196) £429,987 (£215,690)
Vaginal
Dysplasia
£104,414 (£140,277) £298 (£201) £0 (£0) £124 (£304) £104,836 (£140,185)
Vulval Dysplasia £44,162 (£30,812) £259 (£245) £0 (£0) £0 (£0) £44,421 (£32,252)
Total £453,369 (£283,653) £110,049 (£27,717) £30,813 (£23,850) £183,017 (£71,720) £777,247 (£390,837)
Total (Inpatient + Outpatient)
Vaginal Cancer 1,906,239 (£101,890) 117,722 (£24,
323)
392,761 (£52,928) 118,909 (£13,365) 2,535,631 (£84,825)
Vulval Cancer 8,094,105 (£572,787) 75,578 (£17,945) 372,474 (£63,309) 274,657 (£60,135) 8,816,813 (£553,570)
Vaginal
Dysplasia
756,513 (£127,879) 1734 (£1212) 6156 (£5286) 3232 (£1146) 767,634 (£113,141)
Vulval Dysplasia 2,601,517 (£115,984) 4453 (£2390) 3262 (£2603) 705 (£1226) 2,609,937 (£113,442)
Total 13,358,373 (£3,259,
701)
199,487 (£56,
700)
774,652 (£218,
346)
397,502 (£129,
209)
14,730,015 (£478,
362)
*Excludes radiotherapy and chemotherapy unbundled costs; (SD Standard deviation); Total numbers are provided in Bold
Fig. 1 Mean annual cost across genital cancer and dysplasia per type of care. *Excludes radiotherapy and chemotherapy unbundled costs a
Inpatient costs b Outpatient costs c Total costs
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expected, a very small proportion of the total cost asso-
ciated with pre-cancers was attributable to unbundled
costs. Across all disease sites, chemotherapy is associated
with the highest cost burden when looking at all
unbundled elements of care.
Vaginal dysplasia has the lowest total cost burden.
This is due to the low patient numbers recorded with
this disease. Vulval cancer places the highest total bur-
den on NHS resources.
Figure 1 illustrates the proportion of costs attributable
to bundled, chemotherapy, radiotherapy, and other
unbundled costs for each disease state, looking at in-
patient costs (Fig. 1a), outpatient costs (Fig. 1b), and
total cost burden (Fig. 1c).
Discussion
This analysis was conducted to investigate the annual
number of patients seen for outpatient and inpatient
care with pre-cancerous and invasive vaginal and vulval
cancer lesions in England and their associated manage-
ment costs. Data were analysed from 2009/10 to 2014/
15, representing the most recent patient records avail-
able at the time of data delivery to the authors.
The study showed that between 2009/10 and 2014/15,
the total cost of pre-cancerous and invasive vaginal and
vulval cancer lesions in English secondary care
amounted to over £14 million per year, with an average
of 4316 patients hospitalised for these conditions and
7077 inpatient spells of care recorded. In addition, ap-
proximately 912 patients attended an outpatient facility
each year. Diagnoses relating to the vulva were most fre-
quent, with on average, 38% of patients diagnosed with
vulval cancer and 36% with vulval dysplasia. Vulval can-
cer also accounted for the largest proportion of overall
costs (60%), at £8.82 million on average per year. The
data further showed an increasing trend in the number
of inpatients admitted for vulval dysplasia over time,
with an 11% increase seen from 2009/10 to 2014/15. Im-
proved diagnostic techniques, lifestyle changes and an
increase in the life expectancy of women over time may
all contribute to this increase. Regardless of the cause,
an increased disease incidence is a concern and should
be addressed.
Our analyses show that the number of patients receiv-
ing outpatient treatment for vaginal dysplasia suddenly
and disproportionately increased from 2012/13 to 2013/
14. HPV testing was introduced as part of the NHS Cer-
vical Screening Programme for England in April 2011.
HPV testing is provided to triage women whose first cy-
tology sample shows borderline nuclear changes or low
grade dyskaryosis and for test of cure at 6 months for
newly treated women with negative, borderline or low
grade dyskaryosis. Those women who are positive for
high risk HPV DNA in either the triage group or test of
cure, including women with negative cytology in the test
of cure group, are referred for further colposcopy. Ac-
cording to the British Society for Colposcopy and Cer-
vical Pathology, some colposcopy services experienced
an increase in referrals for cervical cancer following the
introduction of HPV testing [18]. This, combined with
the increase in outpatient cases seen in the data between
2012 and 2014, raises the question of whether the use of
HPV testing in the low-grade setting may have also led
to more cases of vaginal dysplasia being detected.
When comparing our results to the estimates available
on a European and global scale, the prevalence and eco-
nomic burden of vulval and vaginal cancers have primar-
ily been estimated in the context of cervical cancers and
HPV-attributable anogenital cancers [19–21]. The latest
global prevalence figures. report 8500 and 12,000 cases
of HPV-related vulval and vaginal cancer [19]. The stan-
dalone evidence on the national-level burden of vulval
and vaginal cancers are rare [22] especially within the
English healthcare context [23, 24]. Recent, comparable
primary evidence using similar national-level data from
Scottish [22], French [23, 25], and Danish [26] perspec-
tives has been published; although, with the exception of
Abramowitz et al. [25], the breakdown of radio- and
chemo-therapy costs have not been stratified in these
publications. Abramowitz et al. reported a higher pro-
portion of chemotherapy and radiotherapy treatments
and consequent per patient cost of these treatments in
vaginal cancer cases than in vulval cancer cases. This
was also seen, to a greater extent, in the current study
(3.9-fold increase in per patient costs of chemotherapy
and radiotherapy in vaginal cancer cases versus vulval
cancer cases in the current study compared with a 1.8-
fold increase seen in Abramowitz et al). Consistent with
our study, all these European publications found the per
patient cost of treating vaginal cancers to be higher than
vulval cancer. There is some variation in the way results
have been presented across studies, for example Olsen
et al. 2012 report costs in terms of years since diagnosis,
where the first-year treatment costs were considerably
higher than the second-year costs for treating both can-
cers [26]. Wakeham and Kavanagh (2014) [22] do not
present specific cost estimates but rather review the epi-
demiology of disease [22]. Borget et al. present cost re-
sults in a similar way to the current paper. They find the
costs of vulval cancers in France to be approximately
40% higher than for vaginal cancers [23]. Our findings
indicate a much larger difference in overall costs when
looking at data from England (approximately 250%
higher for vulval cancers). This may in part be due to a
limitation noted in the Borget study where it is stated
that the costs have been underestimated and estimates
of outpatient and daily allowance costs have been based
on several assumptions. Amongst other publications
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using secondary evidence sources [19, 24, 27], a recent
UK modelling study [28] also attempted to estimate the
20-year lifetime treatment-cost of vulval or vaginal can-
cer (£13,650 per case (2011 costs)) [27]. In summary, the
last national level database analysis reporting costs of
these cancers was carried out in 2009 [21, 23, 26], with
the latest published prevalence figures available up till
2011 [4, 22]. Therefore, our study adds the most up-to-
date costs and burden of managing vulval or vaginal
cancers, using longitudinal data from an English per-
spective, to this scarcely researched body of evidence.
Study limitations
This analysis is not without limitations. Firstly, we only
included patients with a relevant primary, secondary or
tertiary diagnosis code in the analyses. Restricting the
presence of an ICD-10 code in this way may have intro-
duced some selection bias. However, including further
diagnoses may have resulted in costs not related to vagi-
nal and vulval cancer being included in the analysis. Sec-
ondly, although it was possible to ascertain whether a
patient had been admitted to hospital multiple times
within the data years extracted, it was not possible to
distinguish between an initial or recurrent patient. Thus,
the estimated mean annual cost per patient reflects the
average costs of all cases incurring costs within that year,
regardless of the timing of their diagnosis. Furthermore,
as ICD-10 codes are the basis for which a diagnosis is
coded, it was not possible to determine the stage of can-
cer at the time of admission. A higher stage would likely
translate to higher costs and resource use. For invasive
cancers, it is reasonable to expect that the number of in-
patients is an accurate reflection of the total patient
numbers, since very few vaginal or vulval cancer patients
will go through their entire treatment pathway as an
outpatient, but this may not hold true for patients with
dysplasia where much more treatment is provided in the
outpatient setting. Furthermore, patients could not be
traced over time and therefore it was not possible to de-
termine how many patients had a hospital event re-
corded in more than one data year. Consequently,
estimations for the total cost per patient for the entire
duration of their treatment could not be calculated. It
was also not possible to segregate HPV-positive cancer
cases from HPV-negative cancer cases in the current
analyses. Rasmussen et al. have shown that patients with
a HPV-positive vulval cancer diagnosis generally have a
more optimistic prognosis than patients who are diag-
nosed with HPV-negative vulval cancer [29]. This may
mean that the costs of treating HPV positive cases differ
to those for HPV negative cases. Further investigation to
determine if there is a difference in costs is needed. Des-
pite these limitations, the present analysis shows that
there is a cost burden of over £14 million per year
associated with the treatment of vaginal and vulval can-
cers in England, in addition to the physical (e.g. pain, fa-
tigue, bowel / urinary difficulties), emotional (e.g.
anxiety, fear, depression) and personal (e.g. returning to
work, adjustments to sex life, (new) relationships) bur-
den felt by the patients themselves and their caregivers
[30].
The present study provides results which inform the
Department of Health and other decision makers about
the costs of vaginal and vulval cancers, consequently
helping them to realise the value of thorough testing for
female genital cancers, as well as endorsing the WHO
ambition of HPV elimination. A recent study in
Australia has suggested that over the next 15 to 20 years,
we will see declines in cervical cancer incidence and
mortality rates due to such screening which will in turn
reduce healthcare related costs [31]. Proper implementa-
tion of HPV immunization programs could increase this
positive impact further as their benefit is not only lim-
ited to reducing cervical cancer cases because they also
protect against other anogenital cancers, such as vaginal
and vulval lesions.
Conclusion
In conclusion, patients with vaginal and vulval cancers
cost the NHS in England over £14 million per year.
Given the association of HPV with approximately 25% of
vulval cancer and 78% of vaginal cancer cases, preventa-
tive measures such as the national HPV immunisation
programme have the potential to reduce the cost burden
on the healthcare system. Taken together with our previ-
ous studies on the costs of anal, penile and head and
neck cancer, this demonstrates the significant – and ris-
ing - burden of HPV-related disease on the health sys-
tem and highlights the importance of acknowledging
that HPV vaccination has the potential to prevent dis-
ease beyond cervical cancer. To ensure optimal use of
NHS resources, it is important that future economic
evaluations of such preventative measures consider the
full burden of HPV related disease.
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